Last reviewed · How we verify
ADSCs
At a glance
| Generic name | ADSCs |
|---|---|
| Also known as | hADSCs |
| Sponsor | Gwo Xi Stem Cell Applied Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Application of Autologous Stem Cells From Adipose Tissue in the Regeneration of Knee Joint Cartilage (PHASE4)
- Repeat Intracerebroventricular Injections of RB-ADSC in Subjects Previously Treated in RBI Protocol RB-ADSC-02 (PHASE1)
- PRP vs AD-SVF in Addition to Marrow Stimulation for Knee Chondral Lesion (PHASE4)
- Efficacy and Safety of ELIXCYTE Intra-articular Injection in Subject With Knee Osteoarthritis (PHASE3)
- Study of Intracerebroventricular Injections of Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild-Moderate Alzheimer's Disease (PHASE2)
- Successful Treatment of Female Pattern Hair Loss With Injection of Nanofat With and Without Platelet-Rich Plasma (NA)
- Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes
- Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADSCs CI brief — competitive landscape report
- ADSCs updates RSS · CI watch RSS
- Gwo Xi Stem Cell Applied Technology Co., Ltd. portfolio CI